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Several studies have demonstrated that allogeneic haema-
topoietic stem cell transplantation has potent antitumour
effect not only against haematological but also against solid
malignancies.1 Main evidence of the potency of GVT effect
is represented by sustained remissions obtained after NST
in patients with metastatic renal cell carcinoma (RCC)
refractory to conventional cytokine-based immunother-
apy.2,3 This evidence supports the notion that RCC
harbours immunogenic peculiarities4–6 that render this
tumour responsive to immunotherapies.7 Interestingly, only
clear cell carcinoma, but not other RCC histotypes, has
been reported to respond to NST.2,8,9 Whether this is due to
the small number of patients receiving NST for RCC other
than those of the clear cell type or due to a real resistance of
other histotypes remains to be deﬁned. We have observed
objective tumour response following NST in a patient with
metastatic papillary RCC.
A 56 year-old male underwent right nephrectomy for
stage II (AJCC criteria-VI Ed.) papillary renal carcinoma.
After 5 years in June 2002, he relapsed in lungs, and left
laterocervical as well as mediastinal lymph nodes. Biopsy of
laterocervical lymph node conﬁrmed the diagnosis of
metastatic papillary renal carcinoma. From July 2002 to
October 2002, he received treatment with 5-ﬂuorouracil,
interleukin-2 and a-interferon with progression of disease.
In January 2003, after signing informed consent, he
received NST from his 72 year-old HLA-identical brother
according to the European Blood and Marrow Transplan-
tation (EBMT) phase I NST protocol for refractory solid
tumours, approved by the Ethical Committee of Ospedale
Niguarda Ca’ Granda.
Pretransplant conditioning regimen consisted of i.v.
cyclophosphamide 60mg/kg once daily on days 3 and
2 and i.v. ﬂudarabine 30mg/m2 once daily from day 7 to
3. On day 0, a total of 2.2 106 CD34þ and 3.2 108
CD3þ donor cells/kg (recipient body weight) were
transplanted into the patient. Donor cells were previously
collected from the 72 year-old HLA-identical brother by
blood leukapheresis following administration of Filgrastim
300mg subcutaneously twice a day for 6 consecutive days.
Immunosuppression for GVHD prophylaxis consisted of
cyclosporin and short-course methotrexate. Antimicrobial
therapy followed institutional protocols consisting of
itraconazole for antifungal prophylaxis, acyclovir for
antiviral prophylaxis and ciproﬂoxacin for antibacterial
prophylaxis. The degree of donor–recipient chimerism in
both myeloid and T-cell lineages was assessed by PCR
assay of minisatellite regions.
Engraftment was achieved on day þ 12 and early post-
transplant course was uneventful. Cyclosporin administra-
tion was tapered and discontinued on day þ 120, in the
absence of GVHD and with 60% T-cell donor chimerism.
Clinical evaluation by physical examination and CT scan
performed on days þ 60 and þ 120 (Figure 1a and b)
Figure 1 CT scan of patient at day þ 120 (a, b) and þ 190 after allogeneic transplantation (c, d).
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showed a marked disease progression as compared to
baseline. Full donor T-cell chimerism was obtained on day
þ 150 (Figure 2) along with the appearance of grade 1
cutaneous GVHD, which did not require treatment. On day
þ 190, objective tumour regression 450% was documen-
ted by CT scan (450% reduction of mediastinal and lung
metastases – Figure 1c and d) and by physical examination
(450% response up to limits of physical detection of
laterocervical nodes). At 1 week after evidence of tumour
response, the patient developed hepatic and extensive
mucocutaneous GVHD. Cyclosporine was reinstituted
along with steroids and subsequently mycophenolate.
Despite this therapy, hepatic GVHD progressed to liver
failure, and the patient died on day þ 223 still with
sustained tumour response (Figure 2).
In the present case, regression of papillary RCC
following NST can be attributed to an immune-mediated
effect. In fact, tumour progressed in the early post-
transplant phase, thus indicating that the conditioning
regimen did not affect the course of the disease. In addition,
the clinical response associated with onset of GVHD and
the achievement of full donor chimerism represents indirect
evidence of a GVT effect. This is the ﬁrst demonstration
that NST can generate a meaningful GVT effect in RCC
other than clear cell type. Therefore, this therapeutic
approach should be considered also in less common
histologies of RCC. However, the case reported here
underlines that NST approach, while carrying a high risk
of life-threatening complications, should be proposed only
within controlled trials and when conventional treatments
have failed.
S Secondino
P Pedrazzoli
L Giannetta
I Schiavetto
A Vanzulli
S Siena
SC Divisione Oncologia
Medica Falck and Radiologia,
Ospedale Niguarda Ca’
Granda, Milano, Italy
References
1 Renga M, Pedrazzoli P, Siena S. Present results and perspectives
of allogeneic non-myeloablative hematopoietic stem cell trans-
plantation for treatment of human solid tumors. Ann Oncol
2003; 14: 1177–1184.
2 Childs R, Chernoff A, Contentin N et al. Regression of
metastatic renal-cell carcinoma after non-myeloablative allo-
genic peripheral-blood stem-cell transplantation. N Engl J Med
2000; 343: 750–758.
3 Rini BI, Zimmerman T, Stadler WM et al. Allogeneic stem-cell
transplantation of renal cell cancer after nonmyeloablative
chemotherapy: feasibility, engraftment, and clinical results. J
Clin Oncol 2002; 20: 2017–2024.
4 Van Den Eynde BJ, Gaugler B, Probst-Kepper M et al. A new
antigen recognized by cytolytic T lymphocytes on a human
kidney tumour results from reverse strand transcription. J Exp
Med 1999; 190: 1793–1800.
5 Dumas F, Gala JL, Berteau P et al. Molecular expression of
PSMA mRNA and protein in primary renal tumours. Int J
Cancer 1999; 80: 799–803.
6 Gnarra JR, Tory K, Weng Y et al. Mutations of the VHL
tumour suppressor gene in renal carcinoma. Nat Genet 1994; 7:
85–90.
7 Negrier S, Escudier B, Lasset C et al. Recombinant human inter-
leukin-2, recombinant human interferon alfa 2a, or both in meta-
static renal-cell carcinoma. N Engl J Med 1988; 338: 1272–1278.
8 Ueno NT, Cheng YC, Rondo’n G et al. Rapid induction of
complete donor chimerism by the use of a reduced-intensity
conditioning regimen composed of ﬂudarabine and melphalan
in allogeneic stem cell transplantation for metastatic solid
tumours. Blood 2003; 102: 3829–3836.
9 Bregni M, Dodero A, Peccatori J et al. Nonmyeloablative
conditioning followed by hematopoietic cell allografting and
donor lymphocyte infusions for patients with metastatic renal
and breast cancer. Blood 2002; 99: 4234–4236.
Tumor response
GVHD
T-Cell chimerism
Cyclosporin
**By physical examination and CT scan
*By physical examination only
Days from transplant
24021018015012090600
PD* PR*PR**PD**
100%100%60%50%30%
Figure 2 Relevant clinical and biological parameters of patient following
allogeneic transplantation.
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